All In Biotech

Drug Trial Radar · NCT00535925

Nephropathy In Type 2 Diabetes and Cardio-renal Events

Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events.

Last checked: Nov 19, 2026Latest source record: Aug 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 850 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

850

Actual

Start

Oct 2005

Primary completion

Dec 2011

Study completion May 2019

Sponsor

Lead sponsor
University of Campania Luigi VanvitelliAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 27, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 40 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The NID-2 study, a multicentric study (21 centres enrolled), was planned in two phases: Phase 1(observational study, completed in September 2005): after the identification of a type-2 diabetic population with typical Diabetic Nephropathy (DN), to study of the rate of renal and cardiovascular events during a middle term follow-up. Phase 2(interventional study, started in October 2005): after randomization in two groups, a group (intervention group) is treated with an intensive multifactorial intervention whose aim is to reduce morbidity and mortality due to diabetic complications. The other group (control group) continues the conventional therapy . To avoid bias in the treatment in each center, the randomization was performed for centre.

Conditions

  • Diabetic Nephropathy

Interventions

  • SoC therapyDrug

    the patients have to be treated according the standard good medical practice by any center

  • irbesartanDrug

    Therapy for hypertension: \- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die

  • ramiprilDrug

    Therapy for hypertension: \- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die

  • hydrochlorothiazideDrug

    Therapy for hypertension \- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)

  • furosemideDrug

    Therapy for hypertension \- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)

  • amlodipineDrug

    Therapy for hypertension \- Step 3: amlodipine up to 10 mg/die

  • atenololDrug

    Therapy for hypertension \- Step 4: atenolol up to 100 mg/die

  • doxazosinDrug

    Therapy for hypertension \- Step 5: doxazosin up to 4 mg/die

  • clonidineDrug

    Therapy for hypertension \- Step 6: clonidine

  • insulinDrug

    Therapy for Hyperglycaemia (to achieve HbA1c \<7): \- insulin

  • simvastatinDrug

    Therapy for hypercholesterolemia: \- for reducing LDL cholesterol \< 100 mg/dl: simvastatin up to 80 mg/die

  • fibrateDrug

    Therapy for hypertriglyceridemia \- for reducing triglycerides \< 150 mg/dl and/or increasing HDL cholesterol \> 40-50 mg/dl: a fibrate

  • erythropoietinDrug

    Treatment of anaemia: \- erythropoietin

  • aspirinDrug

    Antiplatelet therapy (in all patients without contraindications): \- aspirin up to 160 mg/die

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. "Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)"Time frame: 4 years (in the case the number of events needed by sample size is not reached at the expected 4-year time frame, primary end point will be assessed after the follow-up phase)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy

    Naples, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.